Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial von Coles, Alasdair J, Dr, Twyman, Cary L, MD, Arnold, Douglas L, Prof, Cohen, Jeffrey A, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Miller, Tamara, MD, Fisher, Elizabeth, PhD, Sandbrink, Rupert, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Oyuela, Pedro, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial von Cohen, Jeffrey A, Prof, Coles, Alasdair J, PhD, Arnold, Douglas L, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Fisher, Elizabeth, PhD, Brinar, Vesna V, MD, Giovannoni, Gavin, Prof, Stojanovic, Miroslav, MD, Ertik, Bella I, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis von Thompson, Sara A. J., Jones, Joanne L., Cox, Amanda L., Compston, D. Alastair S., Coles, Alasdair J.

Volltext

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial von Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.

Volltext

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years von Oh, Jiwon, Achiron, Anat, Celius, Elisabeth G., Chambers, Christina, Derwenskus, Joy, Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Rog, David, Schneider, Jean-Raphael, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin, Compston, D. Alastair S.

Volltext

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis von Cox, Amanda L., Thompson, Sara A. J., Jones, Joanne L., Robertson, Vicki H., Hale, Geoff, Waldmann, Herman, Compston, D. Alastair S., Coles, Alasdair J.

Volltext

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings von Coles, Alasdair J, Cohen, Jeffrey A, Fox, Edward J, Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W, Traboulsee, Anthony, Compston, D. Alastair S, Margolin, David H, Thangavelu, Karthinathan, Chirieac, Madalina C, Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J, Panzara, Michael A, Arnold, Douglas L

Volltext

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy von Havrdova, Eva, Arnold, Douglas L, Cohen, Jeffrey A, Hartung, Hans-Peter, Fox, Edward J, Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W, Traboulsee, Anthony, Compston, D. Alastair S, Margolin, David H, Thangavelu, Karthinathan, Rodriguez, Claudio E, Jody, Darlene, Hogan, Richard J, Xenopoulos, Panos, Panzara, Michael A, Coles, Alasdair J

Volltext

Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations von Pfeffer, Gerald, Burke, Ailbhe, Yu-Wai-Man, Patrick, Compston, D. Alastair S, Chinnery, Patrick F

Volltext

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 von Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.

Volltext

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study von Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S

Volltext

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis von Hill-Cawthorne, Grant A, Button, Tom, Tuohy, Orla, Jones, Joanne L, May, Karen, Somerfield, Jennifer, Green, Alison, Giovannoni, Gavin, Compston, D Alastair S, Fahey, Michael T, Coles, Alasdair J

Volltext

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients von Giovannoni, Gavin, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W, Margolin, David H, Lake, Stephen L, Kaup, Susan M, Panzara, Michael A, Compston, D. Alastair S

Volltext

Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation von Sajic, Marija, Hunt, David P J, Lee, Woojin, Compston, D Alastair S, Schweimer, Judith V, Gregson, Norman A, Chandran, Siddharthan, Smith, Kenneth J

Volltext

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease von Williams-Gray, C. H., Goris, A., Saiki, M., Foltynie, T., Compston, D. A. S., Sawcer, S. J., Barker, R. A.

Volltext

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes von Coles, Alasdair J, MD, Fox, Edward, MD, Vladic, Anton, MD, Gazda, Suzanne K, MD, Brinar, Vesna, MD, Selmaj, Krzysztof W, MD, Bass, Ann Doan-Do, DO, Wynn, Daniel R, MD, Margolin, David H, MD, Lake, Stephen L, ScD, Moran, Susan, MD, Palmer, Jeffrey, MS, Smith, M Shelton, PhD, Compston, D Alastair S, MD

Volltext

Immune competence after alemtuzumab treatment of multiple sclerosis von McCARTHY, Claire L, TUOHY, Orla, COMPSTON, D. Alastair S, KUMARARATNE, Dinakantha S, COLES, Alasdair J, JONES, Joanne L

Volltext

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS von Arnold, Douglas L, Fisher, Elizabeth, Brinar, Vesna V, Cohen, Jeffrey A, Coles, Alasdair J, Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W, Stojanovic, Miroslav, Weiner, Howard L, Lake, Stephen L, Margolin, David H, Thomas, David R, Panzara, Michael A, Compston, D. Alastair S

Volltext

Association of the human leucocyte antigen region with susceptibility to Parkinson's disease von Saiki, Misuzu, Baker, Amie, Williams-Gray, Caroline H, Foltynie, Thomas, Goodman, Reyna S, Taylor, Craig J, Compston, D Alastair S, Barker, Roger A, Sawcer, Stephen J, Goris, An

Volltext

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy von Tuohy, Orla, Costelloe, Lisa, Hill-Cawthorne, Grant, Bjornson, Ingunn, Harding, Katharine, Robertson, Neil, May, Karen, Button, Tom, Azzopardi, Laura, Kousin-Ezewu, Onajite, Fahey, Michael T, Jones, Joanne, Compston, D Alastair S, Coles, Alasdair

Volltext